Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Data Validation01:15

Data Validation

Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer·2026
Same author

Mosaic Chromosomal Alterations Identify Ultra-High Risk Clonal Hematopoiesis in Patients With Lymphoma Undergoing Intensive Chemotherapy.

American journal of hematology·2026
Same author

Risk Factors of Blood Culture Positivity and Mortality in Bloodstream Infections: A Population-Based Study of Patients With B-Cell Malignancies.

European journal of haematology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Comprehensive longitudinal profiling identifies differential frequency, epitope specificity, and effector function of CD8<sup>+</sup> T-cells across COVID-19 disease severities.

EBioMedicine·2026
Same author

Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.

British journal of haematology·2026

Related Experiment Video

Updated: Jun 14, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.2K

Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.

Jelena Jelicic1,2, Karen Juul-Jensen1, Zoran Bukumiric3

  • 1Department of Hematology, Odense University Hospital, Odense, Denmark.

European Journal of Haematology
|December 8, 2025
PubMed
Summary

New eligibility criteria significantly increased the number of patients with diffuse large B-cell lymphoma (DLBCL) eligible for front-line clinical trials. A developed predictive model, the Delphi Trial Prognostic Index (DTPI), better identifies patient risk for improved trial selection.

Keywords:
Delphi surveyclinical trialdiffuse large B cell lymphomaprognostic modelsselection criteria

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Related Experiment Videos

Last Updated: Jun 14, 2026

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.2K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Area of Science:

  • Oncology
  • Clinical Trials
  • Hematology

Background:

  • Identifying eligible patients for front-line diffuse large B-cell lymphoma (DLBCL) clinical trials is challenging due to strict criteria and limitations of existing prognostic indices.
  • The International Prognostic Indices (IPI) do not accurately identify DLBCL patients unlikely to achieve long-term remission with standard therapy.

Purpose of the Study:

  • To evaluate the effectiveness of improved eligibility criteria, derived from a US Delphi survey, for identifying real-world DLBCL patients suitable for clinical trials.
  • To develop a predictive model for progression-free survival and an online calculator for individual risk assessment in trial-eligible DLBCL patients.

Main Methods:

  • A Delphi-method survey established new eligibility criteria for DLBCL clinical trials.
  • The Danish Lymphoma Registry data was used to assess trial eligibility (n=5341).
  • A predictive model (Delphi Trial Prognostic Index - DTPI) was developed using a training cohort (3:1 ratio) and validated on a separate cohort, incorporating eight clinical and laboratory variables.

Main Results:

  • Applying the recommended criteria identified 76.1% (4063/5341) of DLBCL patients as trial-eligible.
  • Inadequate organ function was the reason for exclusion in 7.9% of patients.
  • The DTPI demonstrated superior performance in predicting progression-free survival compared to the International Prognostic Indices.

Conclusions:

  • Revised eligibility criteria enhance the identification of DLBCL patients for front-line clinical trials.
  • The developed predictive model and online calculator offer a more accurate assessment of outcomes for potential trial candidates.
  • The DTPI provides a more precise risk stratification tool than traditional prognostic indices for DLBCL patients.